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SHORT COMMUNICATION
Activity of GR30921X (NSC 382057) and GR63178A (NSC D611615) in
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E. Boven, C.A.M. Erkelens, M. Luning & H.M. Pinedo
Free University Hospital, Department ofOncology, De Boelelaan
Compounds of a new group of pentacyclic pyrroloquinones
have been shown to have activity against several experiment-
al tumour systems. The first product to be considered for
clinical evaluation was GR30921X (NSC 382057) (Figure 1).
The drug appeared to be inactive against L1210 and P388
leukaemias, but active in a range of solid tumours, including
mouse sarcoma 180, rat hepatoma D23, human colon HT29
and human mammary MX-1 xenografts in athymic nude
mice (Fenton et al., 1985). Its mechanism of action, however,
is undetermined. For clinical use the drug had to be formu-
lated as a micro-crystalline suspension in low concentrations
of polyethylene glycol 300 and propylene glycol (PEG/PG) to
allow i.v. administration. In 1985 phase I trials started in a
number of European cancer centers, but were discontinued
with the introduction of the water soluble analogue,
GR63178A.
GR63178A (NSC D611615) (Figure 1) has a similar pre-
clinical efficacy profile to that of GR30921X including
activity against mouse adenocarcinoma MAC 30/T, mouse
colon 38 and the human lung xenograft LX-1 (Fenton et al.,
1989). Its toxicity profile in animals was shown to be
relatively free of side effects and in particular, there was no
evidence of bone-marrow suppression in animal models.
Presently, the drug is in phase I trials in British and Dutch
cancer centres (Cassidy et al., 1989; Eccles et al., 1989,
Verweij et al., 1989).
Secondary screens with a disease-oriented approach have
been developed which utilise a series of human tumour lines,
derived from the same tumour type and grown in nude mice.
These screens may add important information on the poten-
tial clinical activity and the differential capacity of promising
anti-cancer compounds (Winograd et al., 1987; Boven et al.,
1988).
Concurrent with phase I clinical trials, we have investi-
gated GR30921X and GR63178A for their efficacy in a panel
of human ovarian cancer lines to analyse their potential
activity in ovarian cancer in the clinical situation. Female
NMRI/Cpb nude mice (Harlan Cpb, Zeist, Netherlands)
maintained under sterile conditions were used (at the age of
8-10 weeks), 2-3 mm diameter tumour fragments being
implanted in both flanks. The tumour lines studied originated
from various ovarian cancer subtypes (Table I), and had
their own sensitivity patterns to conventional cytostatic drugs
(Boven, 1988). GR30921X (suspended in PEG/PG
1 mgml-') and GR63178A (dissolved in 5% dextrose
1-10mgml-') were kindly provided by Glaxo Group
Research Limited (Greenford, Middlesex, UK). Tumours
were measured weekly in three dimensions and the volume
was calculated by the equation, length x width x thickness
x 0.5. Treatment was started at the time tumours reached a
mean volume between 50 and 150mm3. In each experiment
tumour-bearing mice were randomised to give at least six
animals in the treatment and control group. Drugs were
Correspondence: E. Boven.
Received 12 July 1989; and in revised form 3 January 1990.








Figure 1 Structural formulas of GR3092JX and GR63178A.





Ov.He moderately differentiated mucinous 9
Ov.Me carcinosarcoma 6
Ov.Gr moderately differentiated mucinous 15
FCo clear cell carcinoma 6.5
FMa poorly differentiated mucinous 5.5
FKo moderately differentiated serous 12
Ov.Pe moderately differentiated mucinous 8
Ov.Gl poorly differentiated serous 10
Ov.Ri (C) moderately differentiated serous 11
aCalculated in days from 100mm3 to 200mm3.
administered i.p. at various doses and schedules. According
to the criteria of the experimental design of phase II studies
in human tumour lines the MTD was expressed as the dose
causing the induction of a 10% weight loss within I week
after the first injection (Boven et al., 1988). For evaluation of
treatment, relative tumour volumes were used, which were
calculated with the formula VT!VO; where TT is the volume at
any given day and Vo the volume at the start of treatment.
The ratio of the mean relative volume of treated tumours
over that of control tumours multiplied by 100% (T/C%)
indicated the drug activity. For each experiment the lowest
value within 5 weeks after the last injection was considered
17" Macmillan Press Ltd., 1990 Br. J. Cancer (I990), 61, 709 71 1710 E. BOVEN et al.
Table II Activity of GR30921X and GR63178A at similar doses and schedules in human ovarian cancer lines
GR30921X GR63178A
Tumour Dose Treatment Optimum Dose Treatment Optimum
line (mgkg-') schedule T/C% (day) (mgkg-') schedule T/C% (day)
MRI-H-207 100 q7d x 2 25a (16) 100 q7d x 12 76 (18)
MRI-H-207 12 qd x 12 26a (18) 12 qd x 12 55 (18)
Ov.He 100 q7d x 2 53a (38) 100 q7d x 2 109 (33)
Ov.Me 100 q7d x 2 25 (34) 100 q7d x 2 85 (28)
ap <0.05.
the optimal ratio. Deaths within 2 weeks after the final
injection were considered as toxic deaths, and these animals
were excluded from the study. The drug activity was
evaluated by Student's t test.
Initial experiments with GR30921X against tumour lines
MRI-H-207, Ov.He and Ov.Me (Table II), utilised either
daily or weekly dose schedules at the MTD. With both
schedules a remarkable growth inhibition of treated tumours
could be obtained. After the withdrawal of GR30921X from
clinical studies experiments were carried out with its succes-
sor, GR63178A, at doses and schedules similar to those of
GR30921X. Slight activity was found against MRI-H-207,
though this was less than that previously shown for
GR30921X. In tumour lines Ov.He and Ov.Me efficacy was
not observed. As GR63178A did not result in weight loss,
doses were increased to the MTD using the same schedules
i.e. 200 mg kg-' i.p. on days 0 and 7 or 75 mg kg-' i.p. daily
on days 0-11. Ten different human ovarian cancer lines were
studied either with both regimens or only the daily schedule
(Table III). In general, the daily schedule appeared to be
more effective than the weekly administration (MRI-H-207,
Ov.Gr, FMa and Ov.Pe). Tumour lines MRI-H-207, Ov.He,
Ov.Me and Ov.Pe were the most sensitive to this agent; in
MRI-H-207 and Ov.Pe T/C% was <50%. Daily administra-
tion of GR63178A at a dose of 75 mg kg-' appeared to be
more tolerable than a weekly dose of 200 mg kg-' (0/63 and
3/36 toxic deaths respectively).
From our results with GR30921X and GR63178A studied
at MTD in a panel of human ovarian cancer lines we con-
clude that the efficacy ofGR30921X is superior to that ofthe
water soluble analogue. With GR63178A, presently in phase
Table III Activity of GR63178A at maximum tolerated doses in
human ovarian cancer lines
200mgkg-' i.p. q7dx2 75mgkg-' i.p. qdxl2
Tumour Optimum Toxic Optimum Toxic
line T/C% (day) deaths T/C% (day) deaths
MRI-H-207 85 (22) 1/6 46a (22) 0/6
Ov.He not tested 66a (25) 0/6
Ov.Me not tested 64a (27) 0/6
Ov.Gr 94 (29) 0/6 75 (32) 0/6
FCo 77 (16) 2/6 90 (26) 0/8
FMa 90 (30) 0/6 75 (30) 0/6
FKo 104 (29) 0/6 104 (29) 0/6
Ov.Pe 63a (29) 0/6 50 (29) 0/6
Ov.Gl not tested 100 (35) 0/6
Ov.Ri (C) not tested 64 (29) 0/7
ap <0.05.
I clinical trials, we have shown that daily administration
produces slightly better therapeutic effects than weekly in-
jections. Moderate activity of this compound has been
observed in 2/10 lines (T/C% >25% (50%) investigated.
However, with reference to our previous results with conven-
tional agents in nine of these lines its overall activity is less
than cyclophosphamide (T/C% <25% in 2/9 lines) and
cisplatin (T/C% <25% in 4/9 lines) (Table IV; Boven,
1988). Whether the modest activity of GR63178A in our
panel will reflect responses in ovarian cancer patients, should
be awaited from future phase II clinical trials.
This work was supported by Glaxo Group Research Limited, UK.
Table IV Comparative activity in T/C% of GR63178A, cyclophosphamide and cisplatin in human ovarian
cancer lines
Tumour GR63178A Cyclophosphamide Cisplatin
line 75mgkg-' ip. qdx 12 150mgkg-' i.p. ql4dx2 5mgkg-' i.v. q7dx2
MRI-H-207 46 (+) 0 (++) 0 (++)
Ov.He 66 (-) 90 (-) 44 (+)
Ov.Me 64 (-) 2 (++) 36 (+)
FCo 90 (-) 95 () 4(
FMa 75 (-) 40 (+) 1 (++)
FKo 104 (-) 96 (-) 86 (-)
Ov.Pe 50 (+) 64 (-) 45 (+)
Ov.Gl 100 (-) 56 (-) 23 (++)
Ov.Ri (C) 64 (-) 38 (+) 8 (++)
T/C% >50% no activity (-); >25% 50% moderate activity (+); 25% high activity (++).
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